Currency In USD
| Previous Close | 9.86 |
| Open | 9.8 |
| Day High | 11 |
| Day Low | 9.8 |
| 52-Week High | 16.93 |
| 52-Week Low | 8.48 |
| Volume | 17,862.69 |
| Average Volume | 13,751 |
| Market Cap | 53.68M |
| PE | -4.46 |
| EPS | -2.36 |
| Moving Average 50 Days | 11.48 |
| Moving Average 200 Days | 11.35 |
| Change | 0.66 |
MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers
GlobeNewswire Inc.
Mar 10, 2026 9:30 AM GMT
Selected as a C-Further program with up to ~$1.1 million in non-dilutive, aggregate payments to advance IND-enabling development, with potential for meaningful double-digit downstream commercial revenue participation NEW YORK, March 10, 2026 (GLOBE
MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia
GlobeNewswire Inc.
Feb 04, 2026 2:30 AM GMT
Human lung tissue analyses identify iNKT cell depletion as a mechanistic feature of advanced IPFFindings extend MiNK’s iNKT platform into chronic fibrotic lung disease and support immune restoration strategies in IPF, a large unmet-need market LEXING
MiNK Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease
GlobeNewswire Inc.
Jan 08, 2026 5:00 PM GMT
Non-dilutive public-private funded trial with NIAID STTR & Mary Gooze Clinical Trial and Translation AwardExpands iNKT platform into transplantation with an off-the-shelf, HLA-independent, lymphodepletion-free experimental therapy in patients at risk